Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
1998-08-28
2002-08-27
Crouch, Deborah (Department: 1632)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S380000, C530S381000, C530S386000, C530S392000, C530S395000, C800S007000
Reexamination Certificate
active
06441145
ABSTRACT:
BACKGROUND OF THE INVENTION
A growing number of recombinant proteins are being developed for therapeutic and diagnostic applications; however, many of these proteins may be difficult or expensive to produce in a functional form in the required quantities using conventional methods. Conventional methods involve inserting the gene responsible for the production of a particular protein into host cells such as bacteria, yeast, or mammalian cells, and then growing the cells in culture media. The cultured cells then synthesize the desired protein. Traditional bacteria or yeast systems may be unable to produce many complex proteins in a functional form. While mammalian cells can reproduce complex proteins, they are generally difficult and expensive to grow, and produce only mg/L quantities of protein.
The application of transgenic technology to the commercial production of recombinant proteins in the milk of transgenic animals offers significant advantages over traditional methods of protein production. These advantages include a reduction in the total amount of required capital expenditures, elimination of the need for capital commitment to build facilities early in the product development life cycle, and lower direct production cost per unit for complex proteins. Of key importance is the likelihood that, for certain complex proteins, transgenic production may represent the only technologically and economically feasible method of commercial production.
Antithrombin III (ATIII) is a serine protease inhibitor which inhibits thrombin and the activated forms of factors X, VII, IX, XI, and XII. It is normally present in serum at levels of 14-20 mg/dL. Decreased levels of ATIII may be found in the serum of individuals who have either a hereditary deficiency of ATIII or an acquired deficiency, which can result from a number of pathologic conditions. The conventional treatment for hereditary ATIII deficiency is protein replacement therapy, which may also be effective in treating some acquired deficiencies.
Current methods of obtaining ATIII involves isolating the protease inhibitor from blood plasma. However, the use of plasma-based ATIII presents various problems due to the many components in plasma, including: variation between lots; immunogenicity problems; and biohazardous risks due to viral contamination.
A need exists to develope a method to produce ATIII without the inherent problems of the present process.
SUMMARY OF THE INVENTION
This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII (hATIII) produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetyineuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of human plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
REFERENCES:
patent: 4517294 (1985-05-01), Bock et al.
patent: 4632981 (1986-12-01), Bock et al.
patent: 4873316 (1989-10-01), Meade et al.
patent: 5366894 (1994-11-01), Clark et al.
Mullin et al., “Perspectives Series: Molecular Medicine in Genetically Engineered Animals, Transgenesis in the Rat and Larger Mammals.” J. Clin. Invest. , vol. 98, No. 11, Suppl., S37-S40, 1996.*
Drohan WN, “The Past, Present and Future of Transgenic Bioreactors.” Thrombosis and Haemostasis, vol. 78 (1): 543-547, 1997.*
Cole et al., “Glycoslyation Patterns of Human Proteins Expressed in Transgenic Goat Milk.” Journal of Cellular Biochemistry, Supp. 0 (18D) p. 265, 1994,*
Edmunds et al., “Tissue specific and species differences in the glycosylation pattern of antithrombin III.” Journal of Cellular Biochemistry Suppl., vol. 0 (18D) p. 265, 1994.*
Denman et al., “Transgenic expression of a variant of human tissue-type Plasminogen activator in goat milk: purification and characterization of the recombinant . . . ” Biotechnology, 9:839-843, 1991.
Ebert et al., “Transgenic production of a variant of human tissue-type Plasminogen activator in goat milk: generation of transgenic goats and analysis . . . ” Biotechnology, 9:836-838, 1991.
Bock, S. et al., “Cloning and Expression of the cDNA for Human Antithrombin III”,Nucleic Acids Research,vol. 10 (24), PP. 8113-8125 (1982).
Cole, E. et al., “Glycosylation Patterns of Human Proteins Expressed in Transgenic Goat Milk”, ), pp.I of Cellular Biochemistry,Suppl. 0 (180D), pp. 265 (1994).
Edmunds, T. et al., “Tissue Specific and Species Differences in the Glycosylation Pattern of Antithrombin III”,Journal of Cellular Biochemistry,Supp. 0 (180D), pp. 265 (1994).
Fan, B. et al., “Heterogeneity of Recombinant Human Antithrombin III Expressed in Baby Hamster Kidney Cells”The Journal of Biological Chemistry,vol. 268 (23), pp. 17588-17596 (1993).
Wall, R., “Transgenic Livestock: Progress and Prospects for the Future”,Theriogenology,vol. 45, pp. 57-68 (1996).
Cole Edward S.
DiTullio Paul
Meade Harry
Crouch Deborah
Fish & Richardson P.C.
Genzyme Transgenics, Inc.
LandOfFree
Transgenically produced Antithrombin III does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenically produced Antithrombin III, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenically produced Antithrombin III will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2911929